Circulating Tumor Cell Phenotype Detection Based on Epithelial-mesenchymal Transition Markers Combined with Clinicopathological Risk Has Potential to Better Predict Recurrence in Stage III Breast Cancer Treated with Neoadjuvant Chemotherapy: a Pilot...

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2024 Jul 11

PMID 38990453

Authors

Kai-Ye Du

Shang Wu

Xindi Ma

Yunjiang Liu

Affiliations

Soon will be listed here.

Abstract

Background: The potential value of detecting epithelial-mesenchymal transition (EMT) CTCs in early breast cancer, especially during the neoadjuvant therapy period, requires further investigation. We analyzed dynamic CTC phenotype status, to improve recurrence risk stratification for patients with stage III breast cancers.

Methods: We enrolled 45 patients with stage III breast cancers from 2 clinical trials undergoing neoadjuvant chemotherapy and utilized the CanPatrol CTC enrichment technique pre- and post-chemotherapy to identify CTC phenotypes, including epithelial CTCs, biphenotypic epithelial/mesenchymal CTCs, and mesenchymal CTCs, in peripheral blood samples. Kaplan-Meier analyses were conducted to explore the prognostic value of dynamic change of CTC count and the proportion of CTCs with different phenotypes. Then, redefine the risk stratification based on CTC status and clinicopathological risk in combination.

Results: Increased proportion of M + CTCs was a high-risk CTC status that was associated with decreased DFS (HR, 3.584; 95% CI, 1.057-12.15). In a combined analysis with clinicopathological risk, patients with high-risk tumors had an elevated risk of recurrence compared to patients with low-risk tumors (HR, 4.482; 95% CI, 1.246-16.12). The recurrence risk could be effectively stratified by newly defined risk stratification criteria, with 5-year DFS of 100.0%, 77.3%, and 50.0%, respectively, for low-risk, mid-risk, and high-risk patients (P = 0.0077). Finally, in the ROC analysis, the redefined risk stratification demonstrated higher predictive significance with an AUC of 0.7727, compared to CTC status alone (AUC of 0.6751) or clinicopathological risk alone (AUC of 0.6858).

Conclusion: The proportion of M + CTCs increased after neoadjuvant chemotherapy indicating a higher risk of tumor recurrence. Combining CTC status with clinicopathological risk has potential to redefine the risk stratification of stage III breast cancers and provide improved predictions of relapse.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Afifi A, Saad A, Al-Husseini M, Elmehrath A, Northfelt D, Sonbol M . Causes of death after breast cancer diagnosis: A US population-based analysis. Cancer. 2019; 126(7):1559-1567. DOI: 10.1002/cncr.32648. View

Leone J, Leone B, Tayob N, Hassett M, Leone J, Freedman R . Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Res Treat. 2021; 187(3):843-852. DOI: 10.1007/s10549-021-06121-x. View

Aebi S, Karlsson P, Wapnir I . Locally advanced breast cancer. Breast. 2021; 62 Suppl 1:S58-S62. PMC: 9097810. DOI: 10.1016/j.breast.2021.12.011. View

Mittendorf E, Vila J, Tucker S, Chavez-MacGregor M, Smith B, Fraser Symmans W . The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol. 2016; 2(7):929-36. PMC: 5757376. DOI: 10.1001/jamaoncol.2015.6478. View

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D . Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021; 23(1):149-160. PMC: 9455620. DOI: 10.1016/S1470-2045(21)00589-1. View

Laas E, Labrosse J, Hamy A, Benchimol G, de Croze D, Feron J . Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore. Br J Cancer. 2021; 124(8):1421-1427. PMC: 8039034. DOI: 10.1038/s41416-020-01251-3. View

Masuda N, Lee S, Ohtani S, Im Y, Lee E, Yokota I . Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017; 376(22):2147-2159. DOI: 10.1056/NEJMoa1612645. View

Sundling K, Lowe A . Circulating Tumor Cells: Overview and Opportunities in Cytology. Adv Anat Pathol. 2018; 26(1):56-63. DOI: 10.1097/PAP.0000000000000217. View

10.

Li Y, Mo S, Zhang L, Ma X, Hu X, Huang D . Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study. Eur J Cancer. 2022; 169:198-209. DOI: 10.1016/j.ejca.2022.04.010. View

11.

Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T . Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014; 106(5). PMC: 4112925. DOI: 10.1093/jnci/dju066. View

12.

Guan X, Ma F, Li C, Wu S, Hu S, Huang J . The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun (Lond). 2019; 39(1):1. PMC: 6319003. DOI: 10.1186/s40880-018-0346-4. View

13.

Radovich M, Jiang G, Hancock B, Chitambar C, Nanda R, Falkson C . Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncol. 2020; 6(9):1410-1415. PMC: 7349081. DOI: 10.1001/jamaoncol.2020.2295. View

14.

Yu M, Bardia A, Wittner B, Stott S, Smas M, Ting D . Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013; 339(6119):580-4. PMC: 3760262. DOI: 10.1126/science.1228522. View

15.

Horimoto Y, Tokuda E, Murakami F, Uomori T, Himuro T, Nakai K . Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study. J Transl Med. 2018; 16(1):287. PMC: 6195982. DOI: 10.1186/s12967-018-1663-8. View

16.

Agnoletto C, Corra F, Minotti L, Baldassari F, Crudele F, Cook W . Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset. Cancers (Basel). 2019; 11(4). PMC: 6521045. DOI: 10.3390/cancers11040483. View

17.

Zhang S, Wu T, Peng X, Liu J, Liu F, Wu S . Mesenchymal phenotype of circulating tumor cells is associated with distant metastasis in breast cancer patients. Cancer Manag Res. 2017; 9:691-700. PMC: 5703158. DOI: 10.2147/CMAR.S149801. View

18.

Chen X, Wang J, Fan Y, Luo Y, Zhang P, Li Q . Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice. Clin Breast Cancer. 2021; 21(3):191-198. DOI: 10.1016/j.clbc.2020.09.003. View

19.

Wang L, Hong Y, Ma J, Han M, Zhang S, Shan B . Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis. J Int Med Res. 2020; 48(8):300060520944310. PMC: 7418263. DOI: 10.1177/0300060520944310. View

20.

Xu L, Liu Y, Fan Z, Jiang Z, Liu Y, Ling R . Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy: A Multicenter Cohort Study. Front Oncol. 2021; 11:606477. PMC: 8009183. DOI: 10.3389/fonc.2021.606477. View